-
Enanta announces the official launch of Phase Ia/b clinical study on EDP-514 for HBV infection
Time of Update: 2020-06-09
Recently, Enanta Pharmaceutical (http:// Company (http:// announced the launch of Phase Ia/b clinical study on the treatment of HBV infection with lead core inhibitor EDP-514 (Part 1) EDP-514
-
Early clinical trials of individualized new antigen cancer vaccine have extended progression in patients with melanoma, non-small cell lung cancer and bladder cancer
Time of Update: 2020-06-09
Today, Neon Therapeutics company (http:// announced that its personalized new antigen cancer vaccine extends the progression of melanoma, non-small cell lung cancer (NSCLC) and bladder cancer pat
-
Horizon Pharma applies to FDA for approval of teprotumumab for active thyroid eye disease
Time of Update: 2020-06-09
Horizon Pharmaceuticals (http:// , (http:// recently announced that it had filed a biologics licensing application (BLA) with the u.S Food and Drug (http:// Administration ( FDA (http:// fo
-
ODAC supports the first triple set stimulation factor 1 receptor inhibitor pexidartinib for the treatment of symptomated tendoncytoma
Time of Update: 2020-06-09
TGCT, also known as pigmentation fluffy conjure skateitis (PVNS), or tendon cytoblastoma (GCT-TS), is a rare non-malignant tumor with localized aggression It can affect the joints, sacs and tendons
-
Ibtini and venetoclax get FDA approval for treatment of chronic lymphocytic leukemia
Time of Update: 2020-06-09
recently, the New England Journal of Medicine recently launched a major study from the MD Anderson Cancer Center, in which two existing drugs, (http:// a beautiful "combination punch" in the trea
-
FDA approves Piqray (alpelisib) pills in combination with fulvestrant for treatment of advanced or metastatic breast cancer
Time of Update: 2020-06-09
recently, the U.S Food and Drug (http:// Administration ( http:// announced that the Ppelray (alpelisib) pill and fulvestrant combination therapy has been approved for the treatment of hormone
-
FDA grants Aeglea's lead therapy pegzilarginase (polyethyl glycol arginase) breakthrough drug
Time of Update: 2020-06-09
Aeglea BioTherapeutics company (http:// announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has granted the lead therapy pegzilarginase (polyglycol arginase) to tre
-
FDA approves gene tektronix antibody conjugate drug Polivy for treatment of incurable diffuse large B-cell lymphoma in adult patients
Time of Update: 2020-06-09
today, the United States The FDA (http:// announced the accelerated approval of gene tektronix's antibody conjugate drug (http:// Polatuzumab vedotin-piiq, in combination with benzoisande and
-
GlaxoSmithKline and Innoviva announce positive results from Phase III clinical study of new lung disease drug Trelegy Ellipta for asthma treatment
Time of Update: 2020-06-09
recently, British drugcompany GlaxoSmithKline (GSK) and partner Innoviva jointly announced the positive results of the critical phase III clinical study CAPTAIN (NCT02924688) for the treatment of as
-
Sarepta's treatment of DMD antisense RNA drug Exondys 51 (eteplirsen) 3 trials yield positive results
Time of Update: 2020-06-09
Recently, a newly published study showed that Sarepta Therapeutics company (http:// treats Duchenne's muscular dystrophy (DMD) antonymic rna drug (http:// Exo ndirsen, all of which achieved po
-
FDA approves Grifols company Xembify for treatment of primary immunodeficiency disease in patients 2 years of age and older
Time of Update: 2020-06-09
recently, Grifols company (http:// announced that Xembify (subcutaneous immunoglobulin, 20%) has been approved by the U.S Food Drug (http:// Regulatory Authority ( FDA (http:// ) for the trea
-
Viela Bio CD19 monoclonal antibody inebilibb Phase 3 clinical trial reaches primary endpoint and critical secondary endpoint
Time of Update: 2020-06-09
NMOSD is a rare severe neuroinflammatory autoimmune disease Eighty percent of NMOSD patients produce autoantibodies against a water channel protein called AQP4 in the body These self-targeting antib
-
Arrowhead ARO-APOC3 is eligible for FDA grant
Time of Update: 2020-06-09
FCS is a serious rare genetic disease with a prevalence of 1/1000000, usually caused by a single gene mutation that causes very high levels of triglycerides, usually more than 900 mg/dL recently, A
-
Keystone Pharmaceuticals Announces Application for Listing of New AM Drug TIBSOVO (ivosidenib)
Time of Update: 2020-06-09
Keystone Pharmaceuticals announced that it has submitted a third application for the listing of the new drug (http:// of the new drug (http:// of the Of Recurrent/Incuratability Acute Myeloid L
-
Pfizer's anticoagulant Fragmin approved by FDA to treat pediatric patients with recurrent venous thrombosis
Time of Update: 2020-06-09
Fragmin, the anticoagulant owned by Pfizer, the global bio pharmaceutical http:// giant, was approved by the FDA (http:// This is the first drug (http:// approved for the treatment of pediat
-
Azurity's quasi-Katerzia oral fluid is approved by the U.S. FDA
Time of Update: 2020-06-09
recently, The u.S Food and Drug (http:// Administration ( FDA (http:// has approved Katerzia (amlodiodia, 1mg/mL) oral fluid (1mg/mL) for the treatment of hypertension in children and adults
-
FDA approves listing of Pfizer biosimilar Zirabev-bvzr
Time of Update: 2020-06-09
recently, Pfizer announced that it The FDA (http:// approved the listing of its biosimilar, Zirabev-bvzr about Zirabev Zirabev is a biosimilar to the heavy anticancer drug (http:// bevacizum
-
Rohingya Pharmaceuticals cephalosporine capsules approved by the State Drug Administration
Time of Update: 2020-06-09
recently, Shandong Luoxin Pharmaceutical Group Limited Company (http:// (hereinafter referred to as "Roxin Pharmaceuticals") cephalosporine capsules were approved by the State Pharmaceutical (h
-
Qilu Pharmaceuticals myeloma drug to nale amine "Chipyi" officially listed
Time of Update: 2020-06-09
multiple Myeloma (MM) is a malignant blood tumor in which plasma cells proliferate abnormally in the bone marrow, which occurs in middle-aged and elderly people, with typical symptoms such as bone p
-
France's Valbiotis announces positive top-line data for Valedia IIA clinical study
Time of Update: 2020-06-09
recently, (http:// of Valbiotis , France, published positive top-line data for clinical studies in Valedia (active ingredient: TOTUM-63) IIA the study, conducted in people with prediabetes, asses
